Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
Azd0780 – Application in Therapy and Current Clinical Research
AZD0780 (Laroprovstat; PCSK9-IN-12; AZD-0780) | CAS 2455427-91-3 ...
Azd0780 – Aplicación en terapia e investigaciones clínicas actuales
AZD0780 | EX-A6975 | PCSK9抑制剂 | TargetMol
AZD0780 | Inhibitor | TargetMol
AZD0780 for High Cholesterol Clinical Trial 2025 | Power
Study on the Effects of AZD0780 on Cholesterol Levels in Adults Aged 18 ...
AZD0780 | PCSK9 inhibitor | CAS 2455427-91-3 | Selleck
Badanie wpływu AZD0780 na poziom cholesterolu LDL u pacjentów z ...
ACC 2025: AZD0780 shows significant LDL-C reduction in PURSUIT Phase ...
AstraZeneca’s AZD0780 Shows Significant LDL Reduction in Phase IIb Trial
AZD0780 | PCSK9 inhibitor | Axon 4259 | Axon Medchem
AstraZeneca’s AZD0780 cuts LDL-C by 50% in Phase IIb trial - Clinical ...
Ad 7780 | PDF | Analog To Digital Converter | Filter (Signal Processing)
AD7380 | PDF | Analog To Digital Converter | Sampling (Signal Processing)
AstraZeneca's Oral PCSK9 Inhibitor AZD0780 Cleared for Phase III Trial ...
DHC-AZ2D-AZ5D SM 987971901 | PDF | Alternating Current | Electrical ...
Oral Pcsk9 Inhibitor | PDF | Low Density Lipoprotein | Cholesterol
Laroprovstat (AZD0780)
An Oral PCSK9 Inhibitor for Treatment of Hypercholesterolemia: The ...
化合物AZD0780 | 2455427-91-3
阿斯利康公布口服PCSK9抑制剂AZD0780的临床数据
阿斯利康口服PCSK9小分子抑制剂AZD0780临床数据亮眼，降低胆固醇水平近80%！
Laroprovstat (AZD0780, AZD-0780) | PCSK9 inhibitor | Probechem Biochemicals
阿斯利康：小分子PCSK9抑制剂启动中国三期临床
AZD0780; EX-A6975; laroprovstatum; laroprovstat - China Shanghai ...
Bella Vita Clinical Research | Cape Town
研究进展 | AZD0780（一种新型口服小分子PCSK9抑制剂）治疗高胆固醇血症的有效性和安全性研究 - 知乎
puls | 高コレステロール血症治療における経口PCSK9阻害薬AZD0780の有効性：PURSUITランダム化試験
阿斯利康AZD0780薄膜衣片在中国获批临床 拟用于血脂异常治疗_新浪财经_新浪网
Abstract 4359604: Model-Based Evaluation of LDL-C Lowering for ...
阿斯利康PCSK9小分子抑制剂AZD0780在华获批临床，针对高血脂人群
1期临床在他汀基础上使用AZD0780胆固醇降幅达78%——药研快讯
AZD0780, Novel Oral PCSK9 Inhibitor, Demonstrates Major LDL Cholesterol ...
AZD0780, a novel oral PCSK9 inhibitor, demonstrated significant LDL ...
AD780BNZ Datasheet(PDF) - Analog Devices
Study of laroprovstat (AZD0780) to reduce heart attack, stroke and ...
AstraZeneca Launches Phase 1 Study on AZD0780: A Potential Game-Changer ...
【速递】口服生物利用度提高，阿斯利康PCSK9小分子加入竞争|阿斯利康_新浪财经_新浪网
AZ78M08D Datasheet(PDF) - BCD Semiconductor Manufacturing Limited
口服PCSK9抑制剂AZD0780治疗动脉粥样硬化性心血管疾病（ASCVD）-印塔健康官网
【Drug Hunter】2024 年 5 月特别关注小分子药物 - 知乎
AstraZeneca initiates Phase III clinical trial in China for its oral ...
First-Time Disclosures of Drug Candidates in infiniSee xREAL• BioSolveIT
【速递】口服生物利用度提高，阿斯利康PCSK9小分子加入竞争医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
AstraZeneca Completes Phase 1 Drug-Drug Interaction Study for ...
Laroprovstat (AZD0780) | PCSK9 Inhibitor | MedChemExpress
阿斯利康AZD0780薄膜衣片：中国首获临床许可，挑战血脂异常治疗难题 - 知乎
AZD0780, inhibitorul oral PCSK9 care normalizează LDL-C la pacienții ...
Estudio de enfermedad cardiovascular - CeCim
